Therapeutic Solutions International (TSOI) 10-K 17 Apr 18 2017 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	Apr. 16, 2018	Dec. 31, 2017	Jun. 30, 2017
Details
Registrant Name		THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.
Registrant CIK		1,419,051
SEC Form		10-K
Period End date		Dec. 31, 2017
Fiscal Year End		--12-31
Trading Symbol		tsoi
Tax Identification Number (TIN)		451,226,465
Number of common stock shares outstanding	832,801,713
Public Float			$ 1,491,152
Filer Category		Smaller Reporting Company
Current with reporting		Yes
Voluntary filer		No
Well-known Seasoned Issuer		No
Amendment Flag		false
Document Fiscal Year Focus		2,017
Document Fiscal Period Focus		FY
Entity Incorporation, State Country Name		Nevada
Entity Address, Address Line One		4093 Oceanside Boulevard, Suite B
Entity Address, City or Town		Oceanside
Entity Address, State or Province		California
Entity Address, Postal Zip Code		92,056
City Area Code		(760)
Local Phone Number		295-7208
Entity Listing, Par Value Per Share	$ 0.001

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Current Assets
Cash and cash equivalents	$ 29	$ 21,910
Inventory	1,515	36,435
Prepaid expenses and other current assets	1,054	14,304
Total current assets	2,598	72,649
Assets, Noncurrent	23,927	32,226
Total assets	26,525	104,875
Current liabilities:
Accounts payable	343,810	327,592
Accrued expenses and other current liabilities	432,640	135,164
Convertible notes payable, net of discount of $28,541 and $0, at December 31, 2017 and 2016, respectively	27,459	0
Notes payable-related parties	429,201	221,451
Derivative Liability, Current	107,769	0
Total current liabilities	1,340,879	684,207
Long-term Debt, Excluding Current Maturities	0	75,500
Shareholders' deficit:
Preferred shares	0	0
Common shares	806,501	740,251
Additional paid-in capital	3,147,811	2,878,111
Accumulated deficit	(5,268,666)	(4,273,194)
Total shareholders' deficit	(1,314,354)	(654,832)
Total liabilities and shareholders' deficit	$ 26,525	$ 104,875

Consolidated Balance Sheets - P

Consolidated Balance Sheets - Parenthetical - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Details
Debt Instrument, Unamortized Discount, Current	$ 28,541	$ 0
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	5,000,000	5,000,000
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	990,000,000	990,000,000
Common Stock, Shares, Issued	806,501,000	740,251,000
Common Stock, Shares, Outstanding	806,501,000	740,251,000

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Details
Net Sales	$ 2,851	$ 5,009
Cost of Goods Sold	823	1,606
Gross Profit	2,028	3,403
Operating Expenses
General and administrative	107,380	120,625
Salaries, wages, and related costs	402,758	355,244
Selling expenses	3,310	1,508
Consulting fees	69,672	356,250
Legal and professional fees	278,069	200,957
Research and development	25,106	10,990
Total operating expenses	886,295	1,045,574
Operating Income (Loss)	(884,267)	(1,042,171)
Other income (expense):
Loss on derivative liability	(83,968)	0
Change in fair value of derivative liability	26,199	0
Interest expense	(53,436)	(20,286)
Total other income (expense)	(111,205)	(20,286)
Net Income (Loss)	$ (995,472)	$ (1,062,457)
Basic and diluted net loss per common share	$ 0	$ 0
Basic and diluted weighted-average common shares outstanding	778,150,315	668,115,789

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders' Deficit - USD ($)	Common Stock	Additional Paid-in Capital	Retained Earnings	Total
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Dec. 31, 2015	$ 541,000	$ 2,440,709	$ (3,210,737)	$ (229,028)
Shares, Outstanding, Beginning Balance at Dec. 31, 2015	541,000,000
Stock Issued During Period, Value, Issued for Services	$ 68,500	219,800		288,300
Stock Issued During Period, Shares, Issued for Services	68,500,000
Common stock issued in exchange for a license agreement	$ 5,451	10,902		16,353
Common stock issued in exchange for a license agreement, shares	5,451,000
Stock Issued During Period, Value, New Issues	$ 125,300	206,700		332,000
Stock Issued During Period, Shares, New Issues	125,300,000
Net Income (Loss)	$ 0	0	(1,062,457)	(1,062,457)
Shares, Outstanding, Ending Balance at Dec. 31, 2016	740,251,000
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Dec. 31, 2016	$ 740,251	2,878,111	(4,273,194)	(654,832)
Stock Issued During Period, Value, Issued for Services	$ 18,500	126,450		144,950
Stock Issued During Period, Shares, Issued for Services	18,500,000
Stock Issued During Period, Value, New Issues	$ 47,750	143,250		191,000
Stock Issued During Period, Shares, New Issues	47,750,000
Net Income (Loss)	$ 0	0	(995,472)	(995,472)
Shares, Outstanding, Ending Balance at Dec. 31, 2017	806,501,000
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Dec. 31, 2017	$ 806,501	$ 3,147,811	$ (5,268,666)	$ (1,314,354)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Cash flows from operating activities:
Net Income (Loss)	$ (995,472)	$ (1,062,457)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock based compensation to consultants	144,950	288,300
Shares issued for license agreement	0	16,353
Accrued interest, notes payable - related parties	28,414	16,244
Loss on derivative liability	83,968	0
Change in fair value of derivative liabilities	(26,199)	0
Amortization of debt discount	27,459	0
Changes in operating assets and liabilities:
Inventory	34,920	(6,759)
Accounts receivable	0	2,184
Prepaid expenses and other current assets	13,250	199,142
Other assets	8,299	(19,750)
Accounts payable	16,218	50,250
Accrued expenses and other current liabilities	297,476	130,752
Net cash used in operating activities	(366,717)	(385,741)
Cash flows from financing activities:
Proceeds from issuance of common stock	191,000	332,000
Proceeds from convertible notes payable	50,000	0
Proceeds from notes payable - related parties	105,721	76,000
Payments on notes payable - related parties	(1,885)	(2,532)
Net cash provided by financing activities	344,836	405,468
Net increase (decrease) in cash	(21,881)	19,727
Cash and cash equivalents	21,910	2,183
Cash and cash equivalents	29	21,910
Supplemental disclosure of cash flow information
Cash paid for interest	3,565	4,040
Income Taxes Paid	0	800
Non-cash investing and financing transactions
Original issuance discount on convertible notes payable	6,000	0
Debt discount recorded in connection with derivative liability	$ 50,000	$ 0

Note 1 - Nature of Business

Note 1 - Nature of Business	12 Months Ended
	Dec. 31, 2017
Notes
Note 1 - Nature of Business	Note 1 – Nature of business Therapeutic Solutions International, Inc. (“TSI” or the “Company”) was organized August 6, 2007 under the name Friendly Auto Dealers, Inc., under the laws of the State of Nevada. In the first quarter of 2011 the Company changed its name from Friendly Auto Dealers, Inc. to Therapeutic Solutions International, Inc., and acquired Splint Decisions, Inc., a California corporation. Currently the Company is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one’s immune system. Activating one’s immune system is now an accepted method to cure certain cancers, reduce recovery time from viral or bacterial infections and to prevent illness. Additionally, inhibiting one’s immune system is vital for reducing inflammation, autoimmune disorders and allergic reactions. Nutraceutical Division ® ® Emvolio, Inc. SandBox Dental Labs, Inc. Management does not expect existing cash as of December 31, 2017 or as of March 31, 2018 to be sufficient to fund the Company’s operations for at least twelve months from the issuance date of these December 31, 2017 financial statements. These financial statements have been prepared on a going concern basis which assumes the Company will continue to realize its assets and discharge its liabilities in the normal course of business. As of December 31, 2017, the Company has incurred losses totaling $5.3 million since inception, has not yet generated material revenue from operations, and will require additional funds to maintain its operations. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern within one year after the consolidated financial statements are issued. The Company’s ability to continue as a going concern is dependent upon its ability to generate future profitable operations and obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they become due. The Company intends to finance operating costs over the next twelve months through its existing financial resources and we may also raise additional capital through equity offerings, debt financings, collaborations and/or licensing arrangements. If adequate funds are not available on acceptable terms, we may be required to delay, reduce the scope of, or curtail, our operations. The accompanying consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation and Significant Accounting Policies	12 Months Ended
	Dec. 31, 2017
Notes
Note 2 - Basis of Presentation and Significant Accounting Policies	Note 2 – Basis of presentation and significant accounting policies These consolidated financial statements have been prepared by management assuming that the Company will be able to continue as a going concern and realize its assets and discharge its liabilities in the normal course of business. However, certain conditions noted above currently exist which raise substantial doubt about the Company’s ability to continue as a going concern. These financial statements do not include any adjustments to the amounts and classifications of assets and liabilities that might be necessary should the Company be unable to continue as a going concern. If we become unable to continue as a going concern, we may have to liquidate our assets, and might realize significantly less than the values at which our net assets are carried on our financial statements, and stockholders may lose all or part of their investment in our common stock. The accompanying financial statements do not reflect any adjustments related to the outcome of this uncertainty. Principles of Consolidation The accompanying consolidated financial statements include the accounts of Therapeutic Solutions International, Inc. and its subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. Derivative Liabilities A derivative is an instrument whose value is “derived” from an underlying instrument or index such as a future, forward, swap, option contract, or other financial instrument with similar characteristics, including certain derivative instruments embedded in other contracts and for hedging activities. As a matter of policy, the Company does not invest in separable financial derivatives or engage in hedging transactions. However, the Company entered into certain debt financing transactions in fiscal 2017, as disclosed in Note 5, containing certain conversion features that have resulted in the instruments being deemed derivatives. We evaluate such derivative instruments to properly classify such instruments within equity or as liabilities in our financial statements. Our policy is to settle instruments indexed to our common shares on a first-in-first-out basis. The classification of a derivative instrument is reassessed at each reporting date. If the classification changes as a result of events during a reporting period, the instrument is reclassified as of the date of the event that caused the reclassification. There is no limit on the number of times a contract may be reclassified. Instruments classified as derivative liabilities are remeasured using the Black-Scholes model at each reporting period (or upon reclassification) and the change in fair value is recorded on our consolidated statement of operations. We recorded $107,769 of derivative liabilities at December 31, 2017. Use of Estimates Estimates were made relating to valuation allowances, impairment of assets, share-based compensation expense and accruals. Actual results could differ materially from those estimates. Comprehensive Loss Comprehensive loss for the periods reported was comprised solely of the Company’s net loss. LOSS PER SHARE Basic loss per share is computed by dividing net income available to common stockholders by the weighted average number of common shares outstanding during the period of computation. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if potential common shares had been issued, if such additional common shares were dilutive. Since we had net losses for all the periods presented, basic and diluted loss per share are the same, and additional potential common shares have been excluded as their effect would be antidilutive. As of December 31, 2017, a total of 158,677,686 potential common shares, consisting of shares underlying outstanding convertible notes payable were excluded as their inclusion would be antidilutive. Depreciation and Amortization Depreciation is calculated using the straight line method over the estimated useful lives of the assets. Amortization is computed using the straight line method over the term of the agreement. Intangible Assets Intangible assets consisted primarily of intellectual properties such as proprietary nutraceutical formulations. Intellectual assets are capitalized in accordance with ASC Topic 350 “Intangibles – Goodwill and Other.” Long-lived Assets In accordance with ASC 360, Property, Plant and Equipment, the carrying value of intangible assets and other long-lived assets is reviewed on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value. Income Taxes The Company accounts for income taxes under ASC 740 "Income Taxes," "Accounting for Income Taxes" “Accounting for Uncertainty in Income Taxes – an Interpretation of FASB Statement No. 109.” Stock-Based Compensation Compensation expense for stock issued to employees is determined as the fair value of consideration or services received or the fair value of the equity instruments issued, whichever is more reliably measured. Recent Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. ASU 2016-02 will be effective for the Company in the first quarter of 2019 and will be adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company is currently evaluating the impact of this standard on its consolidated financial statements. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). The new standard is based on the principle that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 will be effective for the Company in the first quarter of 2018 and allows for full retrospective or a modified retrospective adoption approach. The adoption of this standard is not expected to have a material impact on the Company’s financial position or results of operations.

Note 3 - Restricted Cash

Note 3 - Restricted Cash	12 Months Ended
	Dec. 31, 2017
Notes
Note 3 - Restricted Cash	Note 3 – Restricted cash Included in non-current asset is a $10,000 certificate of deposit with an annual interest rate of 0.6%. This certificate matures on June 17, 2018, and is used as collateral for a Company credit card, pursuant to a security agreement dated June 20, 2011.

Note 4 - Fixed assets

Note 4 - Fixed assets	12 Months Ended
	Dec. 31, 2017
Notes
Note 4 - Fixed assets	Note 4 – Fixed assets Fixed assets consist of the following: December 31, 2017 December 31, 2016 Computer Hardware $ 10,747 $ 10,747 Office Furniture and Equipment 3,639 3,639 Shipping and Other Equipment 1,575 1,575 Total 15,961 15,961 Accumulated Depreciation (15,961) (15,961) Property and Equipment, net $ - $ -

Note 5 - Convertible Notes Paya

Note 5 - Convertible Notes Payable	12 Months Ended
	Dec. 31, 2017
Notes
Note 5 - Convertible Notes Payable	Note 5 – Convertible notes payable On July 24, 2017 and September 7, 2017, the Company entered into two $28,000 convertible promissory notes with a third party for which the proceeds were used for operations. The Company received net proceeds of $50,000 and thus a $6,000 original issuance discount Derivative liability These On July 24, 2017 and September 7, 2017, the convertible note issuance dates, the Company valued the conversion feature resulting in initial liability of $133,968. Since the fair value of the derivatives were in excess of the proceeds received of $50,000, a full discount to The Company amortizes the discounts over the term of the convertible promissory notes using the interest method. During the year

Note 6 - Notes Payable - Relate

Note 6 - Notes Payable - Related Parties	12 Months Ended
	Dec. 31, 2017
Notes
Note 6 - Notes Payable - Related Parties	Note 6 – Notes payable-related parties Notes payable-related parties consist of: 2017 2016 Note payable – Scientific Advisory Board Member, unsecured, including interest at 10% per annum, with a maturity date of December 31, 2018 $ 15,868 $ 14,721 Three notes payable – Chief Executive Officer, unsecured, including interest at 8%, 10% and 10% per annum, respectively, with maturity dates of December 31, 2018. 132,366 120,330 Note payable – Chief Financial Officer, unsecured, including interest at 8% per annum, with a maturity date of December 31, 2018, 92,800 86,400 Two notes payable – Business Advisory Board Member, unsecured, including interest at 8% and 10% per annum, convertible into common stock at $0.005 and $0.004, respectively, with maturity dates of April 20, 2018 188,167 75,500 $ 429,201 $ 296,951

Note 7 - Related party transact

Note 7 - Related party transactions	12 Months Ended
	Dec. 31, 2017
Notes
Note 7 - Related party transactions	Note 7 – Related party transactions On January 22, 2016, we issued 2,500,000 shares of common stock, valued at $.0035 per share to a director of the Company for services. On February 26, 2016, we issued 1,000,000 shares of common stock, valued at $.0025 per share to a director of the Company for services. On March 7, 2016, we issued 10,000,000 shares of common stock, valued at $.004 per share to a director of the Company for services. On March 21, 2016, we issued 100,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On September 16, 2016, we issued 12,500,000 shares of common stock, valued at $.004 per share, for an investment in the Company’s Private Placement. On October 18, 2016, we issued 40,000,000 shares valued at $.0045 to the officers and directors of the Company for services. On March 21, 2016, we issued 100,800,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On November 11, 2016, we issued a six month convertible note in the amount of $75,000 with an annual interest rate of 8% to a related party. As of December 31, 2017, the Company accrued officers’ salary of $391,100 as of December 31, 2017. On January 17, 2017 , we issued 12,500,000 shares of common stock , valued at $0.004 per share, for an investment in the Company’s Private Placement to a related party. On March 2, 2017 , we issued 12,500,000 shares of common stock , valued at $0.004 per share, for an investment in the Company’s Private Placement to a related party. On April 20, 2017, we issued a six month convertible note in the amount of $100,000 with an annual interest rate of 10% to a related party. On October 20, 2017, we issued 12,500,000 shares of common stock, valued at $0.004 per share, for an investment in the Company’s Private Placement to a related party.

Note 8 - Income Taxes

Note 8 - Income Taxes	12 Months Ended
	Dec. 31, 2017
Notes
Note 8 - Income Taxes	Note 8 – Income taxes The Company is subject to United States federal and state income taxes at an approximate rate of 30%. The reconciliation of the provision for income taxes at the United States federal statutory rate compared to the Company’s income tax expense as reported is as follows: December 31, 2017 2016 Expected income tax at statutory rate $ (338,188) $ (360,963) State Tax 272 - Permanent differences 829 1,437 Change in valuation allowance (223,742) - Change in tax rate 561,529 359,526 Other 100 - Provision for income taxes $ 800 $ – The provision for income tax of $800 is included in general and administrative expense on the accompanying consolidated statements of operations. The significant components of deferred income tax assets and liabilities at December 31, 2017 and 2016 are as follows: December 31, 2017 2016 Net operating loss carry-forward $ 1,208,949 $ 1,262,691 Valuation allowance (1,208,949) (1,262,691) Net deferred income tax asset $ – $ – The Company has net operating losses carried forward of approximately $4.3 million and $3.3 million as of December 31, 2017 and 2016, respectively, available to offset taxable income in future years which expire beginning in fiscal 2032. As of and for the years ended December 31, 2017 and 2016, management does not believe the Company has any uncertain tax positions. Accordingly, there are no unrecognized tax benefits at December 31, 2017 and 2016.

Note 9 - Legal proceedings

Note 9 - Legal proceedings	12 Months Ended
	Dec. 31, 2017
Notes
Note 9 - Legal proceedings	Note 9 – Legal proceedings From time to time, claims are made against us in the ordinary course of business, which could result in litigation. Claims and associated litigation are subject to inherent uncertainties and unfavorable outcomes could occur, such as monetary damages, fines, penalties or injunctions prohibiting us from selling one or more products or engaging in other activities. The occurrence of an unfavorable outcome in any specific period could have a material adverse effect on our results of operations for that period or future periods. However, as of the date of this report, management believes the outcome of currently identified potential claims and lawsuits will not have a material adverse effect on our financial condition or results of operations.

Note 10 - Subsequent Events

Note 10 - Subsequent Events	12 Months Ended
	Dec. 31, 2017
Notes
Note 10 - Subsequent Events	Note 10 – Subsequent events On January 26, 2018, we issued 2,424,242 shares of common stock for the conversion of $8,000 of convertible note dated July 24, 2017 plus interest. On February 1, 2018, we issued 6,376,471 shares of common stock for the conversion of $20,000 of convertible note dated July 24, 2017 plus interest. On , 201 , we issued 1 , 00,000 shares of common stock, valued at $0.004 per share, for an investment in the Company’s Private Placement to a related party

Note 2 - Basis of Presentatio17

Note 2 - Basis of Presentation and Significant Accounting Policies: Principles of Consolidation (Policies)	12 Months Ended
	Dec. 31, 2017
Policies
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements include the accounts of Therapeutic Solutions International, Inc. and its subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.

Note 2 - Basis of Presentatio18

Note 2 - Basis of Presentation and Significant Accounting Policies: Derivative Liabilities (Policies)	12 Months Ended
	Dec. 31, 2017
Policies
Derivative Liabilities	Derivative Liabilities A derivative is an instrument whose value is “derived” from an underlying instrument or index such as a future, forward, swap, option contract, or other financial instrument with similar characteristics, including certain derivative instruments embedded in other contracts and for hedging activities. As a matter of policy, the Company does not invest in separable financial derivatives or engage in hedging transactions. However, the Company entered into certain debt financing transactions in fiscal 2017, as disclosed in Note 5, containing certain conversion features that have resulted in the instruments being deemed derivatives. We evaluate such derivative instruments to properly classify such instruments within equity or as liabilities in our financial statements. Our policy is to settle instruments indexed to our common shares on a first-in-first-out basis. The classification of a derivative instrument is reassessed at each reporting date. If the classification changes as a result of events during a reporting period, the instrument is reclassified as of the date of the event that caused the reclassification. There is no limit on the number of times a contract may be reclassified. Instruments classified as derivative liabilities are remeasured using the Black-Scholes model at each reporting period (or upon reclassification) and the change in fair value is recorded on our consolidated statement of operations. We recorded $107,769 of derivative liabilities at December 31, 2017.

Note 2 - Basis of Presentatio19

Note 2 - Basis of Presentation and Significant Accounting Policies: Use of Estimates (Policies)	12 Months Ended
	Dec. 31, 2017
Policies
Use of Estimates	Use of Estimates Estimates were made relating to valuation allowances, impairment of assets, share-based compensation expense and accruals. Actual results could differ materially from those estimates.

Note 2 - Basis of Presentatio20

Note 2 - Basis of Presentation and Significant Accounting Policies: Comprehensive Loss (Policies)	12 Months Ended
	Dec. 31, 2017
Policies
Comprehensive Loss	Comprehensive Loss Comprehensive loss for the periods reported was comprised solely of the Company’s net loss.

Note 2 - Basis of Presentatio21

Note 2 - Basis of Presentation and Significant Accounting Policies: Loss Per Share (Policies)	12 Months Ended
	Dec. 31, 2017
Policies
Loss Per Share	LOSS PER SHARE Basic loss per share is computed by dividing net income available to common stockholders by the weighted average number of common shares outstanding during the period of computation. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if potential common shares had been issued, if such additional common shares were dilutive. Since we had net losses for all the periods presented, basic and diluted loss per share are the same, and additional potential common shares have been excluded as their effect would be antidilutive. As of December 31, 2017, a total of 158,677,686 potential common shares, consisting of shares underlying outstanding convertible notes payable were excluded as their inclusion would be antidilutive.

Note 2 - Basis of Presentatio22

Note 2 - Basis of Presentation and Significant Accounting Policies: Depreciation and Amortization (Policies)	12 Months Ended
	Dec. 31, 2017
Policies
Depreciation and Amortization	Depreciation and Amortization Depreciation is calculated using the straight line method over the estimated useful lives of the assets. Amortization is computed using the straight line method over the term of the agreement.

Note 2 - Basis of Presentatio23

Note 2 - Basis of Presentation and Significant Accounting Policies: Intangible Assets (Policies)	12 Months Ended
	Dec. 31, 2017
Policies
Intangible Assets	Intangible Assets Intangible assets consisted primarily of intellectual properties such as proprietary nutraceutical formulations. Intellectual assets are capitalized in accordance with ASC Topic 350 “Intangibles – Goodwill and Other.”

Note 2 - Basis of Presentatio24

Note 2 - Basis of Presentation and Significant Accounting Policies: Long-lived Assets (Policies)	12 Months Ended
	Dec. 31, 2017
Policies
Long-lived Assets	Long-lived Assets In accordance with ASC 360, Property, Plant and Equipment, the carrying value of intangible assets and other long-lived assets is reviewed on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value.

Note 2 - Basis of Presentatio25

Note 2 - Basis of Presentation and Significant Accounting Policies: Income Taxes (Policies)	12 Months Ended
	Dec. 31, 2017
Policies
Income Taxes	Income Taxes The Company accounts for income taxes under ASC 740 "Income Taxes," "Accounting for Income Taxes" “Accounting for Uncertainty in Income Taxes – an Interpretation of FASB Statement No. 109.”

Note 2 - Basis of Presentatio26

Note 2 - Basis of Presentation and Significant Accounting Policies: Stock-Based Compensation (Policies)	12 Months Ended
	Dec. 31, 2017
Policies
Stock-Based Compensation	Stock-Based Compensation Compensation expense for stock issued to employees is determined as the fair value of consideration or services received or the fair value of the equity instruments issued, whichever is more reliably measured.

Note 2 - Basis of Presentatio27

Note 2 - Basis of Presentation and Significant Accounting Policies: Recent Accounting Pronouncements (Policies)	12 Months Ended
	Dec. 31, 2017
Policies
Recent Accounting Pronouncements	Recent Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. ASU 2016-02 will be effective for the Company in the first quarter of 2019 and will be adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company is currently evaluating the impact of this standard on its consolidated financial statements. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). The new standard is based on the principle that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 will be effective for the Company in the first quarter of 2018 and allows for full retrospective or a modified retrospective adoption approach. The adoption of this standard is not expected to have a material impact on the Company’s financial position or results of operations.

Note 4 - Fixed assets_ Property

Note 4 - Fixed assets: Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2017
Tables/Schedules
Property, Plant and Equipment	December 31, 2017 December 31, 2016 Computer Hardware $ 10,747 $ 10,747 Office Furniture and Equipment 3,639 3,639 Shipping and Other Equipment 1,575 1,575 Total 15,961 15,961 Accumulated Depreciation (15,961) (15,961) Property and Equipment, net $ - $ -

Note 6 - Notes Payable - Rela29

Note 6 - Notes Payable - Related Parties: Notes payable, Related Parties (Tables)	12 Months Ended
	Dec. 31, 2017
Tables/Schedules
Notes payable, Related Parties	2017 2016 Note payable – Scientific Advisory Board Member, unsecured, including interest at 10% per annum, with a maturity date of December 31, 2018 $ 15,868 $ 14,721 Three notes payable – Chief Executive Officer, unsecured, including interest at 8%, 10% and 10% per annum, respectively, with maturity dates of December 31, 2018. 132,366 120,330 Note payable – Chief Financial Officer, unsecured, including interest at 8% per annum, with a maturity date of December 31, 2018, 92,800 86,400 Two notes payable – Business Advisory Board Member, unsecured, including interest at 8% and 10% per annum, convertible into common stock at $0.005 and $0.004, respectively, with maturity dates of April 20, 2018 188,167 75,500 $ 429,201 $ 296,951

Note 8 - Income Taxes_ Schedule

Note 8 - Income Taxes: Schedule of Components of Income Tax Expense (Benefit) (Tables)	12 Months Ended
	Dec. 31, 2017
Tables/Schedules
Schedule of Components of Income Tax Expense (Benefit)	December 31, 2017 2016 Expected income tax at statutory rate $ (338,188) $ (360,963) State Tax 272 - Permanent differences 829 1,437 Change in valuation allowance (223,742) - Change in tax rate 561,529 359,526 Other 100 - Provision for income taxes $ 800 $ –

Note 8 - Income Taxes_ Schedu31

Note 8 - Income Taxes: Schedule of Deferred Tax Assets and Liabilities (Tables)	12 Months Ended
	Dec. 31, 2017
Tables/Schedules
Schedule of Deferred Tax Assets and Liabilities	December 31, 2017 2016 Net operating loss carry-forward $ 1,208,949 $ 1,262,691 Valuation allowance (1,208,949) (1,262,691) Net deferred income tax asset $ – $ –

Note 1 - Nature of Business (De

Note 1 - Nature of Business (Details)	12 Months Ended
	Dec. 31, 2017
Details
Entity Incorporation, Date of Incorporation	Aug. 6, 2007
Entity Information, Former Legal or Registered Name	Friendly Auto Dealers
Entity Incorporation, State Country Name	Nevada

Note 3 - Restricted Cash (Detai

Note 3 - Restricted Cash (Details)	12 Months Ended
	Dec. 31, 2017USD ($)
Details
Restricted Cash, Current	$ 10,000
Restricted Cash, Current, Nature of Restriction, Description	used as collateral for a Company credit card

Note 4 - Fixed assets_ Proper34

Note 4 - Fixed assets: Property, Plant and Equipment (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Computer Equipment
Property, Plant and Equipment, Gross	$ 10,747	$ 10,747
Office Equipment
Property, Plant and Equipment, Gross	3,639	3,639
Other Transportation Equipment
Property, Plant and Equipment, Gross	1,575	1,575
Property, Plant and Equipment, Gross	15,961	15,961
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	(15,961)	(15,961)
Property, Plant and Equipment, Net	$ 0	$ 0

Note 5 - Convertible Notes Pa35

Note 5 - Convertible Notes Payable (Details)	12 Months Ended
	Dec. 31, 2017USD ($)$ / shares
Debt Instrument, Description	Company entered into two $28,000 convertible promissory notes with a third party for which the proceeds were used for operations
Debt Instrument, Interest Rate, Stated Percentage	12.00%
Debt Instrument, Convertible, Terms of Conversion Feature	convertible to shares of the Company's common stock 180 days after issuance
Amortization to Interest Expense | $	$ 27,459
Discount Balance remaining to be amortized | $	$ 28,541
Conversion feature
Fair Value Assumptions, Expected Dividend Rate	0.00%
Fair Value Assumptions, Expected Term	9 months 7 days
Conversion feature | Minimum
Fair Value Assumptions, Conversion Price	$ 0.003
Share Price	$ 0.008
Fair Value Assumptions, Expected Volatility Rate	299.00%
Fair Value Assumptions, Risk Free Interest Rate	1.21%
Conversion feature | Maximum
Fair Value Assumptions, Conversion Price	$ 0.004
Share Price	$ 0.009
Fair Value Assumptions, Expected Volatility Rate	319.00%
Fair Value Assumptions, Risk Free Interest Rate	1.23%
Revalued Derivative Liabilities
Fair Value Assumptions, Conversion Price	$ 0.003
Share Price	$ 0.008
Fair Value Assumptions, Expected Dividend Rate	0.00%
Fair Value Assumptions, Risk Free Interest Rate	1.31%
Revalued Derivative Liabilities | Minimum
Fair Value Assumptions, Expected Volatility Rate	330.00%
Fair Value Assumptions, Expected Term	3 months 29 days
Revalued Derivative Liabilities | Maximum
Fair Value Assumptions, Expected Volatility Rate	341.00%
Fair Value Assumptions, Expected Term	5 months 12 days

Note 6 - Notes Payable - Rela36

Note 6 - Notes Payable - Related Parties: Notes payable, Related Parties (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Note payable - Scientific Advisory Board Member, unsecured, including interest at 10% per annum, with a maturity date of December 31, 2018
Long-term Debt	$ 15,868	$ 14,721
Three notes payable - Chief Executive Officer, unsecured, including interest at 8%, 10% and 10% per annum, respectively, with maturity dates of December 31, 2018.
Long-term Debt	132,366	120,330
Note payable - Chief Financial Officer, unsecured, including interest at 8% per annum, with a maturity date of December 31, 2018,
Long-term Debt	92,800	86,400
Two notes payable - Business Advisory Board Member, unsecured, including interest at 8% and 10% per annum, convertible into common stock at $0.005 and $0.004, respectively, with maturity dates of April 20, 2018
Long-term Debt	188,167	75,500
Long-term Debt	$ 429,201	$ 296,951

Note 7 - Related party transa37

Note 7 - Related party transactions (Details)	12 Months Ended
	Dec. 31, 2017USD ($)$ / sharesshares
Debt Instrument, Interest Rate, Stated Percentage	12.00%
Transaction 1
Transaction date	Jan. 22, 2016
Sale of Stock, Description of Transaction	we issued 2,500,000 shares of common stock
Stock Issued During Period, Shares, New Issues | shares	2,500,000
Sale of Stock, Price Per Share | $ / shares	$ 0.0035
Transaction 2
Transaction date	Feb. 26, 2016
Sale of Stock, Description of Transaction	we issued 1,000,000 shares of common stock
Stock Issued During Period, Shares, New Issues | shares	1,000,000
Sale of Stock, Price Per Share | $ / shares	$ 0.0025
Transaction 3
Transaction date	Mar. 7, 2016
Sale of Stock, Description of Transaction	we issued 10,000,000 shares of common stock
Stock Issued During Period, Shares, New Issues | shares	10,000,000
Sale of Stock, Price Per Share | $ / shares	$ 0.004
Transaction 4
Transaction date	Mar. 21, 2016
Sale of Stock, Description of Transaction	we issued 100,000,000 shares of common stock
Stock Issued During Period, Shares, New Issues | shares	100,000,000
Sale of Stock, Price Per Share | $ / shares	$ 0.0025
Transaction 5
Transaction date	Sep. 16, 2016
Sale of Stock, Description of Transaction	we issued 12,500,000 shares of common stock
Stock Issued During Period, Shares, New Issues | shares	12,500,000
Sale of Stock, Price Per Share | $ / shares	$ 0.004
Transaction 6
Transaction date	Oct. 18, 2016
Sale of Stock, Description of Transaction	we issued 40,000,000 shares
Stock Issued During Period, Shares, New Issues | shares	40,000,000
Sale of Stock, Price Per Share | $ / shares	$ 0.0045
Transaction 7
Transaction date	Mar. 21, 2016
Sale of Stock, Description of Transaction	we issued 100,800,000 shares of common stock
Stock Issued During Period, Shares, New Issues | shares	100,800,000
Sale of Stock, Price Per Share | $ / shares	$ 0.0025
Transaction 8
Transaction date	Nov. 11, 2016
Sale of Stock, Description of Transaction	we issued a six month convertible note
Debt Instrument, Face Amount | $	$ 75,000
Debt Instrument, Interest Rate, Stated Percentage	8.00%
Transaction 9
Transaction date	Dec. 31, 2017
Sale of Stock, Description of Transaction	the Company accrued officers’ salary of $391,100
Transaction 10
Transaction date	Jan. 17, 2017
Sale of Stock, Description of Transaction	we issued 12,500,000 shares of common stock
Stock Issued During Period, Shares, New Issues | shares	12,500,000
Sale of Stock, Price Per Share | $ / shares	$ 0.004
Transaction 11
Transaction date	Mar. 2, 2017
Sale of Stock, Description of Transaction	we issued 12,500,000 shares of common stock
Stock Issued During Period, Shares, New Issues | shares	12,500,000
Sale of Stock, Price Per Share | $ / shares	$ 0.004
Transaction 12
Transaction date	Apr. 20, 2017
Sale of Stock, Description of Transaction	we issued a six month convertible note
Debt Instrument, Face Amount | $	$ 100,000
Debt Instrument, Interest Rate, Stated Percentage	10.00%
Transaction 13
Transaction date	Oct. 20, 2017
Sale of Stock, Description of Transaction	we issued 12,500,000 shares of common stock
Stock Issued During Period, Shares, New Issues | shares	12,500,000
Sale of Stock, Price Per Share | $ / shares	$ 0.004

Note 8 - Income Taxes_ Schedu38

Note 8 - Income Taxes: Schedule of Components of Income Tax Expense (Benefit) (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Details
Expected income tax at statutory rate	$ (338,188)	$ (360,963)
State Tax	272	0
Permanent differences	829	1,437
Change in valuation allowance	(223,742)	0
Change in tax rate	561,529	359,526
Other	100	0
Provision for income taxes	$ 800	$ 0

Note 8 - Income Taxes_ Schedu39

Note 8 - Income Taxes: Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Details
Net operating loss carry-forward	$ 1,208,949	$ 1,262,691
Valuation allowance	(1,208,949)	(1,262,691)
Net deferred income tax asset	$ 0	$ 0

Note 10 - Subsequent Events (De

Note 10 - Subsequent Events (Details)	12 Months Ended
	Dec. 31, 2017$ / sharesshares
Event 1
Subsequent Event, Date	Jan. 26, 2018
Subsequent Event, Description	we issued 2,424,242 shares of common stock
Stock Issued During Period, Shares, New Issues	2,424,242
Event 2
Subsequent Event, Date	Feb. 1, 2018
Subsequent Event, Description	we issued 6,376,471 shares of common stock
Stock Issued During Period, Shares, New Issues	6,376,471
Event 3
Subsequent Event, Date	Feb. 20, 2018
Subsequent Event, Description	we issued 15,000,000 shares of common stock, valued at $0.004 per share, for an investment in the Company’s Private Placement to a related party
Stock Issued During Period, Shares, New Issues	15,000,000
Sale of Stock, Price Per Share | $ / shares	$ 0.004
Event 4
Subsequent Event, Date	Feb. 20, 2018
Subsequent Event, Description	and 2,500,000 shares of common stock, valued at $0.0062 for consulting services
Stock Issued During Period, Shares, New Issues	2,500,000
Sale of Stock, Price Per Share | $ / shares	$ 0.0062